ACLX - Gilead Arcellx close agreement on developing T-cell therapy for multiple myeloma
- Gilead Sciences' ( NASDAQ: GILD ) Kite unit and Arcellx ( NASDAQ: ACLX ) have finalized a collaboration for the further development of CART-ddBCMA, the latter company's lead treatment for relapsed or refractory multiple myeloma.
- The T-cell therapy, currently in phase 2, will be jointly commercialized in the US and by Kite in other countries.
- Arcellx ( ACLX ) received a $225M upfront payment and $100M equity investment from Kite as part of the deal .
For further details see:
Gilead, Arcellx close agreement on developing T-cell therapy for multiple myeloma